Losartan Potassium Tablet, Film Coated
Product Images NDC 68071-2690

Product Visual Gallery

This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Losartan Potassium (NDC 68071-2690). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Nucare Pharmaceuticals,inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Pdp (68071 2690 3)

This is a description of Losartan Potassium 50mg tablets manufactured by NuCare Pharmaceuticals. The NDC number is 68071-2690-3 and the lot number is 00000. The tablets come in a package of 30 with a serial number of 0000000002. The MFR NDC number is 43547-361-03 and the expiration date is 00-00. The label contains instructions on dosage and storage, and includes warning to keep out of reach of children and store at controlled temperature 68-77°F.*

FDA Label Image

Chemical Structure (Spl Image1 Structure1)

FDA Label Image

Figure 1 (Spl Image2 Figure1)

The text is describing a comparison between two medications, Atenolol and Losartan Potassium, in terms of their effects on the primary endpoint in a study. The study tracked patients for a period of 66 months and found an adjusted risk reduction of 13% with Losartan Potassium compared to Atenolol. The statistical significance of this finding is reported as p=0.021.*

FDA Label Image

Figure 2 (Spl Image3 Figure2)

This appears to be a comparison of two medications, Atenolol and Losartan Potassium, for their effectiveness in reducing the risk of fatal/non-fatal stroke. The adjusted risk reduction for Losartan Potassium is 25% with a p-value of 0.001. The data is presented in a table showing the percentage of patients with fatal/non-fatal stroke over the course of 66 months.*

FDA Label Image

Figure 3 (Spl Image4 Figure3)

This is a table or figure showing the primary endpoint events, including stroke, fatal/non-fatal, among demographic subgroups, stratified by age, gender, race, ISH, diabetes, and history of CVD, in a study comparing Losartan Potassium and Atenolol. The table also includes the number of events, event rate, hazard ratio, and 95% confidence interval. The symbols are proportional to sample size. The results are adjusted for baseline Framingham risk score and level of electrocardiographic left ventricular hypertrophy.*

FDA Label Image

Figure 4 (Spl Image5 Figure4)

This appears to be a chart representing the percentage of patients with an event, with two groups being compared: one group taking Losartan Potassium, and the other taking a placebo. It appears that after 48 months, 60% of patients taking placebo experienced an event, while 40% of patients taking Losartan Potassium experienced an event. The risk reduction is reported as 16.1% with a significance level of p=0.022.*

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.